IDH-Mutant Gliomas as a Distinct Disease Entity

Dr. Timothy Cloughesy introduces the program focusing on managing IDH-mutant gliomas after surgery, joined by Dr. Ugur Sener from Mayo Clinic. The discussion establishes IDH-mutant gliomas as a unique disease entity distinct from IDH-wild-type glioblastomas.

Dr. Sener characterizes the typical patient population as young adults in their 20s-40s who present with first-time seizures and face long-lasting, difficult-to-control disease at an early life stage. This creates unique challenges requiring consideration of long-term treatment consequences including neurocognitive outcomes, treatment toxicities, duration of therapy, and progression management strategies.

The molecular understanding developed over recent decades has identified IDH mutations as the defining characteristic, whether in astrocytomas or oligodendrogliomas. These patients typically present with seizures and follow more indolent disease courses compared to older glioblastoma patients who present with rapidly progressive neurological symptoms.

The classification system recognizes astrocytomas graded 2 to 4 and oligodendrogliomas graded 2 to 3, all unified by the presence of IDH mutations. Additional molecular markers like homozygous CDKN2A/B deletion automatically designate grade 4 astrocytomas, representing important advances in molecular tumor classification.

Standard pre-vorasidenib management involved initial surgical resection followed by either watchful surveillance for younger patients with good resections and lower-grade tumors, or earlier radiation and chemotherapy for older patients or those with visible residual disease. Higher-grade tumors typically received immediate radiation and chemotherapy regardless of resection extent.

The differentiation between grades relies on conventional histology including microvascular proliferation, necrosis presence, mitotic figures, and proliferative indices, though clinical behavior can vary within grade designations.